Skip to main content

What's Trending in GLP-1 Telehealth

The latest GLP-1 news, active provider discounts, and trending treatment guides — updated hourly.

GLP-1 Weekly

What's Happening This Week

In the News

STAT NewsSTAT+: CMS, FDA team up to fast-track reimbursement for breakthrough devicesFederal regulators are proposing a new, faster Medicare coverage pathway for medical devices deemed by the FDA as breakthroughs.Apr 23, 2026STAT NewsSTAT+: AMA calls for regulatory crackdown on chatbots, wellness AIIn this edition of STAT Health Tech: OpenAI's targets clinicians, AMA's call for regulatory crackdown, and bargain-basement telehealth visits.Apr 23, 2026STAT NewsSTAT+: Pharmalittle: We’re reading about cheap telehealth visits, pharma withholding meds in Europe, and moreDrugmakers have begun using coupons to discount the cost of telehealth visits with clinicians who can prescribe their drugsApr 23, 2026STAT NewsAcross 7 hearings, RFK Jr. talks a new, more moderate MAHADiscount telehealth visits, maternal mortality data, and more health news from Morning RoundsApr 23, 2026STAT NewsSTAT+: Will bargain-basement telehealth visits help pharma drive drug scripts?As links between pharmaceutical companies and telehealth providers grow, health policy experts and legislators have sounded alarms.Apr 23, 2026

From STAT News

Our Take

FDA issues 30 warning letters to compounding telehealth companies

The FDA warned 30 telehealth providers for making misleading claims about compounded GLP-1s and threatened legal action without further notice; patients at any of those companies should know their provider is now under active federal enforcement pressure

FDA.gov

Hims & Hers and Novo Nordisk resolve dispute, enter brand partnership

Hims will now carry Novo Nordisk's branded GLP-1 medications and stop marketing most compounded alternatives, so current Hims patients will eventually only have access to branded versions, which cost significantly more than compounded ones

Healthcare Brew

Novo Nordisk formally asks FDA to ban all semaglutide compounding

Joining Eli Lilly, Novo Nordisk has petitioned the FDA to prohibit compounding pharmacies from making semaglutide, which would eliminate the $149–$299/month compounded option in favor of the $900+/month branded Ozempic or Wegovy

Pharma Phorum

Medicare set to begin covering GLP-1 medications for obesity at $50/month

Starting April 2026, eligible Medicare beneficiaries with obesity will be able to access GLP-1 medications at a $50/month cost-share through a new federal coverage model, with Medicaid expansion planned for May 2026

CMS.gov

FDA decision on Eli Lilly's oral GLP-1 pill orforglipron due April 10

If the FDA approves orforglipron on its April 10 PDUFA date, it would be the first once-daily oral GLP-1 pill available in the U.S., giving patients who want to avoid injections a potential option within weeks

BioSpace
Subscribe to GLP-1 Weekly

Latest Guides

Trending Guides